MA43870A - Inhibition de la protéine associée à l'ataxie télangiectasie et à rad3 (atr) - Google Patents

Inhibition de la protéine associée à l'ataxie télangiectasie et à rad3 (atr)

Info

Publication number
MA43870A
MA43870A MA043870A MA43870A MA43870A MA 43870 A MA43870 A MA 43870A MA 043870 A MA043870 A MA 043870A MA 43870 A MA43870 A MA 43870A MA 43870 A MA43870 A MA 43870A
Authority
MA
Morocco
Prior art keywords
rad3
atr
inhibition
protein associated
ataxia telangiectasia
Prior art date
Application number
MA043870A
Other languages
English (en)
Inventor
Ozan Alkan
Daryl C Drummond
Bolin Geng
Dmitri B Kirpotin
Alexander Koshkaryev
Suresh K Tipparaju
Original Assignee
Celator Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celator Pharmaceuticals Inc filed Critical Celator Pharmaceuticals Inc
Publication of MA43870A publication Critical patent/MA43870A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA043870A 2016-01-11 2017-01-11 Inhibition de la protéine associée à l'ataxie télangiectasie et à rad3 (atr) MA43870A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662277262P 2016-01-11 2016-01-11
US201662420258P 2016-11-10 2016-11-10
US201762444172P 2017-01-09 2017-01-09

Publications (1)

Publication Number Publication Date
MA43870A true MA43870A (fr) 2021-05-26

Family

ID=59311885

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043870A MA43870A (fr) 2016-01-11 2017-01-11 Inhibition de la protéine associée à l'ataxie télangiectasie et à rad3 (atr)

Country Status (12)

Country Link
US (4) US10570119B2 (fr)
EP (2) EP3936153A1 (fr)
JP (3) JP6918829B2 (fr)
KR (2) KR102461219B1 (fr)
CN (2) CN108697811B (fr)
AU (2) AU2017207299B2 (fr)
DK (1) DK3402532T3 (fr)
ES (1) ES2921008T3 (fr)
MA (1) MA43870A (fr)
MX (1) MX2018008507A (fr)
PL (1) PL3402532T3 (fr)
WO (1) WO2017123588A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3402532T3 (da) * 2016-01-11 2022-07-11 Celator Pharmaceuticals Inc Hæmning af ataxia telangiectasia og rad3-relateret protein (atr)
TWI755629B (zh) * 2018-09-13 2022-02-21 台灣微脂體股份有限公司 含鎮靜藥物之緩釋藥物組合物及其用途
EP3866764A4 (fr) * 2018-10-17 2022-07-13 Taiwan Liposome Company, Ltd. Compositions pharmaceutiques à libération prolongée comprenant un agent immunomodulateur et leurs utilisations
KR20230088709A (ko) 2020-10-16 2023-06-20 상하이 드 노보 파마테크 컴퍼니 리미티드 트리헤테로사이클릭 유도체, 이의 약학적 조성물 및 용도

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990610A (en) 1988-08-25 1991-02-05 Applied Analytical Industries, Inc. Method for preparing high potency sucralfate
US5043164A (en) 1989-01-17 1991-08-27 The University Of Tennessee Research Corporation Blood-stable, cholesterol-free liposomes
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0203752D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
DE602004015429D1 (de) 2003-03-11 2008-09-11 Pfizer Prod Inc Pyrazinverbindungen als inhibitoren des transforming growth factor (tgf)
KR101168440B1 (ko) 2003-07-16 2012-07-27 프로티바 바이오쎄라퓨틱스, 인코포레이티드 지질 캡슐화된 간섭 ｒｎａ
KR101462825B1 (ko) 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
GB0411401D0 (en) 2004-05-21 2004-06-23 Tissuomics Ltd Penetrating radiation measurements
AU2005272586A1 (en) 2004-08-19 2006-02-23 Icos Corporation Compounds useful for inhibiting CHK1
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
JP5132550B2 (ja) 2005-05-12 2013-01-30 アボット・ラボラトリーズ アポトーシス促進剤
WO2007015632A1 (fr) 2005-08-04 2007-02-08 Cgk Co., Ltd. Inhibiteur d’atm et d’atr
CN101534904B (zh) 2006-09-05 2013-11-06 Abbvie公司 治疗血小板过量的bcl抑制剂
JP5532921B2 (ja) 2007-05-14 2014-06-25 コニカミノルタ株式会社 リポソーム
EP2370424A1 (fr) 2008-11-10 2011-10-05 Vertex Pharmaceuticals Incorporated Composés utiles comme inhibiteurs de l atr kinase
EP4059932A1 (fr) * 2008-12-19 2022-09-21 Vertex Pharmaceuticals Incorporated Composés utiles en tant qu'inhibiteurs de kinase d'atr
US8884870B2 (en) 2008-12-19 2014-11-11 Immersion Corporation Interactive painting game and associated controller
UY32351A (es) 2008-12-22 2010-07-30 Astrazeneca Ab Compuestos de pirimidinil indol para uso como inhibidores de atr
EP2475661B1 (fr) 2009-09-10 2013-10-23 Novartis AG Sulfonamides en tant qu'inhibiteurs de la famille bcl-2 de proteines pour le traitement du cancer
EP2568984A1 (fr) 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Composés utiles en tant qu'inhibiteurs de l'atr kinase
AU2011253025A1 (en) 2010-05-12 2012-11-29 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2011143425A2 (fr) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Composés utilisables en tant qu'inhibiteurs de la kinase atr
EP2569286B1 (fr) 2010-05-12 2014-08-20 Vertex Pharmaceuticals Inc. Composés utilisables en tant qu'inhibiteurs de la kinase atr
JP5856151B2 (ja) 2010-05-12 2016-02-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼ阻害剤として有用な２−アミノピリジン誘導体
WO2011143419A1 (fr) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Pyrazines utiles en tant qu'inhibiteurs de la kinase atr
US8623869B2 (en) 2010-06-23 2014-01-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CN102485212B (zh) * 2010-12-01 2014-04-09 沈阳药科大学 苹果酸舒尼替尼脂质体及其制备方法
CN102485213A (zh) * 2010-12-01 2012-06-06 沈阳药科大学 伊立替康脂质体及其制备方法
CA2832100A1 (fr) 2011-04-05 2012-10-11 Vertex Pharmaceuticals Incorporated Composes aminopyrazines utiles en tant qu'inhibiteurs de la kinase atr
WO2012178125A1 (fr) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Composés inhibiteurs de la kinase atr
US8822469B2 (en) 2011-06-22 2014-09-02 Vertex Pharmaceuticals Incorporated Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase
WO2012178124A1 (fr) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Composés utiles comme inhibiteurs de la kinase atr
WO2013049720A1 (fr) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Composés utiles en tant qu'inhibiteurs de kinase atr
US20130089626A1 (en) 2011-09-30 2013-04-11 Vertex Pharmaceuticals Incorporated Treating Cancer with ATR Inhibitors
CA2850564A1 (fr) * 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Composes utiles comme inhibiteurs de kinase atr
ES2751741T3 (es) * 2011-09-30 2020-04-01 Vertex Pharma Procedimiento para fabricar compuestos útiles como inhibidores de la quinasa ATR
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071093A1 (fr) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Composés de pyrazine utiles comme inhibiteurs de kinase atr
WO2013071090A1 (fr) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Composés utiles en tant qu'inhibiteurs de la kinase atr
WO2013071088A1 (fr) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Composés utiles comme inhibiteurs de kinase atr
EP2776419B1 (fr) * 2011-11-09 2016-05-11 Vertex Pharmaceuticals Incorporated Composés pyraziniques utiles en tant qu'inhibiteurs de l'atr kinase
US8846918B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
IN2014KN02410A (fr) 2012-04-05 2015-05-01 Vertex Pharma
US8999632B2 (en) * 2012-10-04 2015-04-07 Vertex Pharmaceuticals Incorporated Method for measuring ATR inhibition mediated increases in DNA damage
US8912198B2 (en) * 2012-10-16 2014-12-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
LT3418281T (lt) 2012-12-07 2021-01-11 Vertex Pharmaceuticals Inc. Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2970288A1 (fr) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Composés utiles en tant qu'inhibiteurs de la kinase atr
EP2970289A1 (fr) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Composés utiles en tant qu'inhibiteurs de la kinase atr
RU2736219C2 (ru) 2014-06-17 2020-11-12 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с использованием комбинации ингибиторов снк1 и atr
US20170151339A1 (en) * 2014-06-30 2017-06-01 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
KR20180054657A (ko) 2015-09-30 2018-05-24 버텍스 파마슈티칼스 인코포레이티드 Dna 손상제 및 atr 저해제의 병용물을 사용한 암 치료 방법
DK3402532T3 (da) 2016-01-11 2022-07-11 Celator Pharmaceuticals Inc Hæmning af ataxia telangiectasia og rad3-relateret protein (atr)

Also Published As

Publication number Publication date
US20200399247A1 (en) 2020-12-24
PL3402532T3 (pl) 2022-08-22
AU2023282309A1 (en) 2024-01-18
ES2921008T3 (es) 2022-08-16
CN108697811B (zh) 2023-04-07
US10570119B2 (en) 2020-02-25
KR102461219B1 (ko) 2022-10-31
AU2017207299A1 (en) 2018-08-02
DK3402532T3 (da) 2022-07-11
EP3402532B1 (fr) 2022-04-13
JP2019505584A (ja) 2019-02-28
CN108697811A (zh) 2018-10-23
EP3936153A1 (fr) 2022-01-12
EP3402532A4 (fr) 2019-09-11
JP7439023B2 (ja) 2024-02-27
JP2024023349A (ja) 2024-02-21
KR20180096787A (ko) 2018-08-29
JP2021176879A (ja) 2021-11-11
JP6918829B2 (ja) 2021-08-11
EP3402532A1 (fr) 2018-11-21
KR102558501B1 (ko) 2023-07-21
WO2017123588A1 (fr) 2017-07-20
US11787781B2 (en) 2023-10-17
AU2017207299B2 (en) 2023-09-21
KR20230002511A (ko) 2023-01-05
US11028076B2 (en) 2021-06-08
US20230416236A1 (en) 2023-12-28
US20190135789A1 (en) 2019-05-09
CN116211803A (zh) 2023-06-06
US20210300905A1 (en) 2021-09-30
MX2018008507A (es) 2019-07-04

Similar Documents

Publication Publication Date Title
MA45937A (fr) Inhibiteurs d'amino pyrimidine ssao
SG10201912690PA (en) Protein cage-stabilized pickering emulsions and the use thereof
DK3478712T3 (da) Anti-N3pGlu-amyloidbetapeptid-antistoffer og anvendelser deraf
KR102068915B9 (ko) 조직 인자 경로 억제제 항체 및 그의 용도
ES2970074T3 (es) Inhibidor de ATR y su aplicación
MA43870A (fr) Inhibition de la protéine associée à l'ataxie télangiectasie et à rad3 (atr)
DK3528620T3 (da) Akvakultursystem på åbent hav samt fremgangsmåde
MA49905A (fr) Polyesteramines et polyesterquats
CA185201S (fr) Boucle d'oreilles
ZA202100092B (en) Modified cas9 protein and use thereof
EP3399033A4 (fr) Marqueur peptidique et protéine marquée comprenant celui-ci
DK3524276T3 (da) Biokompatible magnetiske materialer
MA42130A (fr) Combinaisons d'opioïdes et de n-acyléthanolamines
ITUA20162517A1 (it) Composizione per la conservazione/fissazione di materiale biologico
FR3047559B1 (fr) Detecteur d'immersion et aeronef
UA38869S (uk) Логотип «донбас і мирні»
UA38485S (uk) Інтер'єр закладу торгівлі
UA38250S (uk) Ювелірна прикраса «сережки-вішалочки»
FR3078830B1 (fr) " decouplage electromagnetique "
ITUB20160529A1 (it) Materiale multistrato e procedimento di realizzazione di detto materiale multistrato
UA38871S (uk) Логотип «donbass and civilians»
IT201700025477A1 (it) Capo di abbigliamento e relativo sistema di realizzazione
GB201721869D0 (en) The system of identification and positioning of internet of things
ES1211063Y (es) Pieza de joyeria o bisuteria
ITUA20162462A1 (it) "zerbino con disegno ad intarsio e relativo procedimento di lavorazione"